Disease or Syndrome – Page 3

Schott Pharma Invests Over €100M in New Sterile Cartridge Facility at Hungary Site

1 week ago talkbio0Tagged Automation, Diabetes, expansion, Glucagon-Like Peptide 1, Hungary, Impacts, Environmental, Investments, Lukácsháza, Manufacturing, Pharma, pharma packaging, RTU cartridges, Schott, sterile cartridge facility

Schott Pharma; Hungary; sterile cartridge facility; €100 million investment; RTU cartridges; pharma packaging; manufacturing expansion; Lukácsháza; GLP-1 drugs; diabetes; automation; environmental impact

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

1 week ago talkbio0Tagged Autoimmune Diseases, biotech partnerships, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, bispecific, CD19xCD3, Clinical Development, CLN-978, Cullinan, Genrix Bio, Multiple Myeloma, T-Cell engager, velinotamig

Cullinan Therapeutics; Genrix Bio; BCMA bispecific; velinotamig; T-cell engager; autoimmune disease; CD19xCD3; CLN-978; multiple myeloma; clinical development; biotech partnerships

Vigil’s Iluzanebart Fails Phase 2 in Rare Neuro Disease; Sanofi Takeover Remains On Track

1 week ago talkbio0Tagged Agonist, amgen, Hereditary Diffuse Leukoencephalopathy with Spheroids, iluzanebart, Neuro Disease, Sanofi acquisition, TREM2, VG-3927, Vigil

Vigil Neuroscience; iluzanebart; Phase II IGNITE trial; rare neuro disease; ALSP; Sanofi acquisition; Amgen; TREM2 agonist; VG-3927

Ascletis’ Sagimet-Sourced Oral FASN Inhibitor Achieves All Endpoints in Pivotal Acne Study

1 week ago talkbio0Tagged Acne Vulgaris, Ascletis, Biosciences, Chinese study, clinical endpoints, Clinical Trials, Denifanstat, Inhibitor, Lesion, oral FASN, Phase 3, Sagimet

Ascletis; Sagimet Biosciences; denifanstat; oral FASN inhibitor; phase 3 clinical trial; acne vulgaris; clinical endpoints; lesion reduction; Chinese study

Sarepta’s rAAVrh74 Viral Vector Receives FDA Platform Technology Designation for Gene Therapy

1 week ago talkbio0Tagged gene therapy, Infrequent, Muscular Dystrophies, Limb-Girdle, platform technology designation, SRP-9003, United States Food and Drug Administration, Viral Vector

Sarepta Therapeutics; FDA; platform technology designation; rAAVrh74 viral vector; gene therapy; SRP-9003; limb-girdle muscular dystrophy; rare diseases

Ex-HHS Workers Accuse Trump Administration of Using Flawed Data to Justify Mass Firings

1 week ago talkbio0Tagged Agencies, CHARGE Syndrome, disability services, firings, Medicare, Project, public servants, Trump administration

HHS firings; Trump administration; federal workforce; flawed data; Project 2025; agency cuts; disability services; Medicare; public servants

Eli Lilly and Camurus Sign $870M Deal for Long-Acting Obesity Therapies

1 week ago talkbio0Tagged biotech collaboration, Camurus, cardiometabolic health, Drug Development, eli lilly, FluidCrystal technology, incretin drugs, long-acting therapies, Obesity, pharma partnerships

Eli Lilly; Camurus; obesity drugs; long-acting therapies; FluidCrystal technology; incretin drugs; cardiometabolic health; pharma partnerships; drug development; biotech collaboration

FDA Approves Moderna’s Next-Generation Covid Vaccine With Limited Use for Most Healthy People

1 week ago talkbio0Tagged Approved, COVID19 (disease), Elderly (population group), high-risk, Moderna, next-generation Covid vaccine, Omicron, Omicron JN.1, restrictions, Spikevax, United States Food and Drug Administration, Vaccines, Variant

Moderna; FDA approval; mNexspike; next-generation Covid vaccine; vaccine restrictions; Covid-19; Spikevax; elderly; high-risk medical conditions; Omicron JN.1 variant

BioAge Signs Option Agreement for Obesity Asset from Chinese Biotech Following APJ Agonist Setback

1 week ago talkbio0Tagged Agonist, APJ, BioAge, Exercise, incretin therapy, Metabolic Diseases, mimetics, nanobody, Obesity, small molecule agonists

BioAge; JiKang Therapeutics; obesity; APJ agonist; option agreement; nanobody; small molecule agonists; exercise mimetic; incretin therapy; metabolic diseases

Kymera Soars on Early Protein Degrader Data

2 weeks ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, KT-621, Kymera, Phase 1 (qualifier value), Protein Degradation, Metabolic, STAT6 degrader

Kymera Therapeutics; KT-621; STAT6 degrader; protein degradation; Phase 1 clinical trial; autoimmune disease